Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
NCT ID: NCT04376684
Last Updated: 2024-09-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1156 participants
INTERVENTIONAL
2020-05-28
2021-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
NCT02613910
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
NCT01920477
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
NCT04605926
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
NCT04206553
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
NCT01084252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Participants receiving otilimab
Participants (age \>=18 years and \<=79 years) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 1.
Otilimab
Otilimab will be administered once via IV route.
Standard of care
All participants will receive standard of care as per institutional protocol.
Part 1: Participants receiving placebo 1
Participants (age \>=18 years and \<=79 years) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 1.
Placebo 1
Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
Standard of care
All participants will receive standard of care as per institutional protocol.
Part 2: Participants receiving otilimab
Participants (age 70 years or above) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 2.
Otilimab
Otilimab will be administered once via IV route.
Standard of care
All participants will receive standard of care as per institutional protocol.
Part 2: Participants receiving placebo 2
Participants (age 70 years or above) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 2.
Placebo 2
Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
Standard of care
All participants will receive standard of care as per institutional protocol.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Otilimab
Otilimab will be administered once via IV route.
Placebo 1
Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
Placebo 2
Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
Standard of care
All participants will receive standard of care as per institutional protocol.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must:
1. have positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) result (any validated test, for example. reverse transcription polymerase chain reaction \[RT-PCR\] \[performed on an appropriate specimen; for example: respiratory tract sample\])
2. and be hospitalized due to diagnosis of pneumonia (chest X-ray or computerized tomography \[CT\] scan consistent with COVID-19)
3. and be developing new onset of oxygenation impairment requiring any of the following:
1. high-flow oxygen (\>=15L/min)
2. non-invasive ventilation (for example. CPAP, BIPAP)
3. mechanical ventilation \<=48 hours prior to dose
4. and have increased biological markers of systemic inflammation (either C-reactive protein \[CRP\] \>upper limit of normal \[ULN\] or serum ferritin \>ULN).
* No gender restriction.
* Female participants must meet and agree to abide by the contraceptive criteria detailed in the protocol. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* A female participant is eligible to participate if she is not pregnant or breastfeeding or if she is using highly effective contraceptive methods. Women of non-childbearing potential can also participate. A negative highly sensitive pregnancy test at hospital admission or before the first dose of study intervention.
* Capable of giving written informed consent.
* Participants aged 70 years or above at the time of obtaining informed consent.
* Participants must:
1. have positive SARS-CoV-2 result (any validated test, for example. RT-PCR \[performed on an appropriate specimen; for example. respiratory tract sample\])
2. and be hospitalized due to diagnosis of pneumonia (chest X-ray or CT scan consistent with COVID-19).
3. and be developing new onset of oxygenation impairment requiring any of the following:
1. high-flow oxygen (\>=15L/min)
2. non-invasive ventilation (for example. CPAP, BiPAP)
3. mechanical ventilation \<=48 hours prior to dose
4. and have increased biological markers of systemic inflammation (either CRP \>ULN or serum ferritin \>ULN.
* No gender restriction.
* Capable of giving written informed consent.
Exclusion Criteria
* Multiple organ failure according to the investigator's judgement or a Sequential Organ Failure assessment (SOFA score) \>10 if in the ICU.
* Extracorporeal membrane oxygenation (ECMO) hemofiltration/dialysis or high-dose (\>0.15 micrograms \[mcg\]/kilograms \[kg\]/min) noradrenaline (or equivalent) or more than one vasopressor.
* Current serious or uncontrolled medical condition (for example: significant pulmonary disease \[such as severe chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis\], heart failure \[New York Heart Association {NYHA} class III or higher\], renal dysfunction, acute myocardial infarction or acute cerebrovascular accident within the last 3 months) or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.
* Untreated systemic bacterial, fungal, viral, or other infection (other than SARS-CoV-2).
* Known active tuberculosis (TB), history of untreated or incompletely treated active or latent TB, suspected or known extrapulmonary TB.
* Known Human Immunodeficiency Virus (HIV) regardless of immunological status.
* Known hepatitis B surface antigen (HBsAg) and/or anti-hepatitis C virus (HCV) positive.
* Currently receiving radiotherapy, chemotherapy or immunotherapy for malignancy.
* Received monoclonal antibody therapy (for examplee. tocilizumab, sarilumab) within the past 3 months prior to randomization, including intravenous immunoglobulin, or planned to be received, during the study.
* Received immunosuppressant therapy including but not limited to cyclosporin, azathioprine, tacrolimus, mycophenolate, Janus Kinase (JAK) inhibitors (for examplee. baricitinib, tofacitinib, upadacitinib) within the last 3 months prior to randomization or planned to be received during the study.
* History of allergic reaction, including anaphylaxis to any previous treatment with an anti-GM-CSF therapy.
* Received COVID-19 convalescent plasma within 48 hours of randomization.
* Currently receiving chronic oral corticosteroids for a non-COVID-19 related condition in a dose higher than prednisone 10 milligrams (mg) or equivalent per day.
* Treatment with an investigational drug within 30 days of randomization.
* Participating in other drug clinical trials, including for COVID-19.
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>5 times ULN.
* Platelets \<50,000/cubic millimeters (mm\^3)
* Hemoglobin \<=9 grams per deciliter (g/dL)
* Absolute neutrophil count (ANC) \<1.5 times 10\^9/L (neutropenia \>= Grade 2)
* Estimated glomerular filtration rate (GFR) \<=30 milliliters (mL)/min/1.73 meter square (/m\^2).
* Pregnant or breastfeeding females.
* Progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatments, in the opinion of the investigator.
* Multiple organ failure according to the investigator's judgement or a SOFA score \>10 if intubated in the ICU.
* ECMO hemofiltration/dialysis, or more than one inotrope/vasopressor of any class.
* Current serious or uncontrolled medical condition (for example. significant pulmonary disease \[such as severe COPD or pulmonary fibrosis\], heart failure \[NYHA class III or higher\], severe renal dysfunction, acute myocardial infarction or acute cerebrovascular accident within the last 3 months), severe dementia, severe disability, or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.
* Untreated systemic bacterial, fungal, viral, or other infection (other than SARSCoV-2).
* Known active TB, history of untreated or incompletely treated active or latent TB, suspected or known extrapulmonary TB.
* Known HIV regardless of immunological status.
* Known HBsAg and/or anti-HCV positive (participants demonstrating a sustained virologic response (SVR) are not excluded from participation).
* Currently receiving radiotherapy, chemotherapy (hormone based therapies are permitted) or immunotherapy for malignancy.
* Received monoclonal antibody therapy (for example. tocilizumab, sarilumab) within the past 3 months prior to randomization, including intravenous immunoglobulin, or planned to be received during the study.
* Received immunosuppressant therapy including but not limited to cyclosporin, azathioprine, tacrolimus, mycophenolate, JAK inhibitors (for example. baricitinib, tofacitinib, upadacitinib), nintedanib, disease modifying antirheumatic drugs (DMARDs) (for example. methotrexate) within the last 3 months prior to randomization or planned to be received during the study.
* History of allergic reaction, including anaphylaxis to any previous treatment with an anti-GM-CSF therapy.
* Received COVID-19 convalescent plasma within 48 hours of randomization.
* Currently receiving chronic oral corticosteroids for a non-COVID-19 related condition at a dose higher than prednisone 10 mg or equivalent per day.
* Treatment with an investigational drug or substance within 30 days of randomization unless approved by the Medical Monitor.
* Participating in other drug clinical trials, including for COVID-19.
* AST or ALT \>5 times ULN.
* Platelets \<50,000/mm\^3.
* Hemoglobin \<=9 g/dL
* ANC \<1.0 x 10\^9/L (neutropenia \>= Grade 3).
* Estimated GFR \<=30 mL/min/1.73 m\^2.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Winfield, Illinois, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Germantown, Maryland, United States
GSK Investigational Site
Silver Spring, Maryland, United States
GSK Investigational Site
Saint Louis Park, Minnesota, United States
GSK Investigational Site
Saint Paul, Minnesota, United States
GSK Investigational Site
Jackson, Mississippi, United States
GSK Investigational Site
Reno, Nevada, United States
GSK Investigational Site
Buffalo, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Toledo, Ohio, United States
GSK Investigational Site
Doylestown, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Roanoke, Virginia, United States
GSK Investigational Site
Tacoma, Washington, United States
GSK Investigational Site
Milwaukee, Wisconsin, United States
GSK Investigational Site
Munro, Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Córdoba, , Argentina
GSK Investigational Site
Córdoba, , Argentina
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Yvoir, , Belgium
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Saint-Jérôme, Quebec, Canada
GSK Investigational Site
Santiago, , Chile
GSK Investigational Site
Santiago, , Chile
GSK Investigational Site
Bogotá, , Colombia
GSK Investigational Site
Amiens, , France
GSK Investigational Site
Angers, , France
GSK Investigational Site
Argenteuil, , France
GSK Investigational Site
La Roche-sur-Yon, , France
GSK Investigational Site
La Tronche, , France
GSK Investigational Site
Limoges, , France
GSK Investigational Site
Melun, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Pierre-Bénite, , France
GSK Investigational Site
Strasbourg, , France
GSK Investigational Site
Strasbourg, , France
GSK Investigational Site
Valenciennes, , France
GSK Investigational Site
Aurangabad, , India
GSK Investigational Site
Aurangabad, , India
GSK Investigational Site
Hyderabad, , India
GSK Investigational Site
Kolkata, , India
GSK Investigational Site
Kolkata, , India
GSK Investigational Site
Mumbai, , India
GSK Investigational Site
Nagpur, , India
GSK Investigational Site
New Delhi, , India
GSK Investigational Site
Pune, , India
GSK Investigational Site
Pune, , India
GSK Investigational Site
Napoli, Campania, Italy
GSK Investigational Site
Aichi, , Japan
GSK Investigational Site
Kanagawa, , Japan
GSK Investigational Site
Kanagawa, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Saitama, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Mexico City, Mexico City, Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico
GSK Investigational Site
México, , Mexico
GSK Investigational Site
's-Hertogenbosch, , Netherlands
GSK Investigational Site
Breda, , Netherlands
GSK Investigational Site
Enschede, , Netherlands
GSK Investigational Site
Nijmegen, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Lima, , Peru
GSK Investigational Site
Lima, , Peru
GSK Investigational Site
Lima, , Peru
GSK Investigational Site
Bydgoszcz, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Poznan, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Wroclaw, , Poland
GSK Investigational Site
Barnaul, , Russia
GSK Investigational Site
Chelyabinsk, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Nizhny Novgorod, , Russia
GSK Investigational Site
Omsk, , Russia
GSK Investigational Site
Perm, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Ufa, , Russia
GSK Investigational Site
Voronezh, , Russia
GSK Investigational Site
Yekaterinburg, , Russia
GSK Investigational Site
Benoni, Gauteng, South Africa
GSK Investigational Site
Johannesburg, Gauteng, South Africa
GSK Investigational Site
Durban, KwaZulu-Natal, South Africa
GSK Investigational Site
Panorama, , South Africa
GSK Investigational Site
Tygerberg, , South Africa
GSK Investigational Site
Worcester, , South Africa
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
L'Hospitalet de Llobregat, , Spain
GSK Investigational Site
Logroño, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
San Sebastián de Los Reyes/Madrid, , Spain
GSK Investigational Site
Manchester, Greater Manchester, United Kingdom
GSK Investigational Site
Newcastle, Northumberland, United Kingdom
GSK Investigational Site
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Patel J, Bass D, Beishuizen A, Bocca Ruiz X, Boughanmi H, Cahn A, Colombo H, Criner GJ, Davy K, de-Miguel-Diez J, Doreski PA, Fernandes S, Francois B, Gupta A, Hanrott K, Hatlen T, Inman D, Isaacs JD, Jarvis E, Kostina N, Kropotina T, Lacherade JC, Lakshminarayanan D, Martinez-Ayala P, McEvoy C, Meziani F, Monchi M, Mukherjee S, Munoz-Bermudez R, Neisen J, O'Shea C, Plantefeve G, Schifano L, Schwab LE, Shahid Z, Shirano M, Smith JE, Sprinz E, Summers C, Terzi N, Tidswell MA, Trefilova Y, Williamson R, Wyncoll D, Layton M. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). Eur Respir J. 2023 Feb 2;61(2):2101870. doi: 10.1183/13993003.01870-2021. Print 2023 Feb.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
214094
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.